Navigation Links
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Date:6/9/2008

ins forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: the Company's ability to initiate a Phase II clinical study of cysteamine in Huntington's Disease in 2008, if ever; that the potential benefits reflected in preclinical studies in Huntington's Disease models will be beneficial to patients with Huntington's Disease; the Company will successfully develop cysteamine for any indication, including Huntington's Disease; and the Company will be able to comply with regulations to fulfill the criteria for maintaining Orphan Drug Designation for cysteamine for the treatment of Huntington's Disease. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We cau
'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions driven ... record-breaking year across the board for the company. , ... and our Smart Data solutions, our customers were able to ... to record growth for the company in 2014,” said Alok ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to ... independent consultants, Protocol Networks has recently announced its expansion ... years, his company has attracted several clients in The ... well as others. With the success of these engagements, ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... multi-drug ... resistant infections -, NEW HAVEN, Conn., Jan. ... focused on the,development of novel antibiotics for the treatment of antibiotic-resistant,infections, ... 2 clinical trials. The studies will evaluate the safety and,efficacy of ...
... the pharmaceutical and biotechnology ... strengthens specialist expertise, BOSTON, Jan. 3 Observant ... a passion for research excellence,and a commitment to client ... joined the firm as Vice President. Dr. Hartman,s,research has ...
... are using the tiniest organisms on the planet ,bacteria, as ... study featured in the journal Biotechnology and Bioengineering, lead author ... have gained critical insights that may lead to commercialization of ... can use any kind of waste, such as sewage or ...
Cached Biology Technology:Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3Observant LLC Expands Senior Management Team 2Life at the jolt 2Life at the jolt 3Life at the jolt 4
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into your ... the answer to your secret question. What,s your dog,s birthday? Who ... Labs , a digital infrastructure security company, launches the ... comes with usernames, passwords and PINs – 1U TM ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... the most rapidly increasing food production system worldwide through ... 2009 issue of BioScience . The assessment, by ... Ann Arbor, notes that despite well-publicized concerns about ... practiced well, be no more damaging to biodiversity than ...
... has worked out how some newly discovered light sensors ... brain. The report appears online this week in ... small number of nerve cells in the retina that ... retinarods and conesmelanopsin-containing cells are not used for seeing ...
... DNA modification in lung cancer, a team of international researchers ... They say that "silencing" of a single gene in lung ... cells, contributing to cancer development and progression. In the ... journal of the American Association for Cancer Research, they also ...
Cached Biology News:Aquaculture's growth seen as continuing 2Bright lights, not-so-big pupils 2Bright lights, not-so-big pupils 3In lung cancer, silencing one crucial gene disrupts normal functioning of genome 2In lung cancer, silencing one crucial gene disrupts normal functioning of genome 3
... Two separate vials containing 200 ... same sequence used as antigens for ... 160890) To be ... cyclase polyclonal antiserum (Catalog No. 160890) ...
... Clone/PAD: 3B8A10. Immunogen: ... the C-terminal region of ... Specific for the human ... Human (positive control: 293 ...
... The PinPoint™ Vector Sequencing Primer is ... PinPoint™ Xa Vectors (Cat.# V2031, V2051, V2061). ... Xa site at nucleotides 325343, approximately 4050 ... region and can be used to determine ...
... The versatile Zymo-Spin I-96 Plate can be ... manifolds for the large-scale (i.e., 96-well) purification ... polypropylene construction and unique silica-based matrix make ... g DNA or RNA in = 10 ...
Biology Products: